Literature DB >> 15210635

Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia.

Eric Wooltorton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15210635      PMCID： PMC421714          DOI： 10.1503/cmaj.1040882

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

Review 1.  Irritable bowel syndrome.

Authors:  Howard R Mertz
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

Review 2.  Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants.

Authors:  W G Paterson; W G Thompson; S J Vanner; T R Faloon; W W Rosser; R W Birtwhistle; J L Morse; T A Touzel
Journal:  CMAJ       Date:  1999-07-27       Impact factor: 8.262

Review 3.  Tegaserod for the treatment of irritable bowel syndrome.

Authors:  B W Evans; W K Clark; D J Moore; P J Whorwell
Journal:  Cochrane Database Syst Rev       Date:  2004
  3 in total
  4 in total

Review 1.  The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.

Authors:  James H Lewis
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

2.  From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis.

Authors:  Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2017-06-02       Impact factor: 3.199

3.  Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.

Authors:  Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2016-04-12       Impact factor: 3.199

Review 4.  Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.

Authors:  J Tack; M Camilleri; L Chang; W D Chey; J J Galligan; B E Lacy; S Müller-Lissner; E M M Quigley; J Schuurkes; J H De Maeyer; V Stanghellini
Journal:  Aliment Pharmacol Ther       Date:  2012-02-22       Impact factor: 8.171
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.